New Possibilities in Brain Tumor Treatment Through Metabolic Inhibition

This Phase 1b clinical trial, led by the U.S. National Cancer Institute (NCI), successfully confirmed the safety and optimal dose (RP2D) of telaglenastat (CB-839), a glutaminase-1 (GLS1) inhibitor. The drug's unique mechanism, which directly blocks tumor metabolic pathways, is designed to offer a new treatment option for brain tumor patients who exhibit resistance to conventional chemotherapy. Through a 3+3 dose escalation scheme, the final recommended dose was determined to be 800mg twice daily, demonstrating safety without significant dose-limiting toxicities (DLT). This is a key milestone in evaluating whether this novel metabolic inhibitor can cross the challenging blood-brain barrier (BBB) and deliver meaningful clinical value.

Synergistic Mechanism of Triple Combination Therapy

This study focuses on a triple combination of telaglenastat, standard radiation therapy, and temozolomide chemotherapy, rather than telaglenastat alone. When chemoradiation induces DNA damage in tumor cells, telaglenastat inhibits glutamine metabolism, which cancer cells rely on, thereby disrupting the production of intracellular antioxidants such as glutathione. This neutralizes the cancer cells' ability to self-repair and maximizes their sensitivity to radiation and chemotherapy, creating a synergistic effect. This blocking strategy reflects the industry trend of not only inhibiting cell growth but also fundamentally overcoming treatment resistance to existing therapies.

Scientific Rationale for Targeting IDH Gene Mutations

The primary target is patients with isocitrate dehydrogenase (IDH)-mutant diffuse and anaplastic astrocytomas. IDH mutations accumulate the oncometabolite 2-hydroxyglutarate (2-HG) within the tumor and disrupt normal glutamate synthesis, making cancer cells highly dependent on glutamine. From the design of the clinical trial, this is a strategic choice to realize precision medicine by specifically targeting this biological vulnerability. Patient selection based on genetic biomarkers is considered a key factor in increasing the success rate of later-stage clinical trials and reducing development costs.

Competitive Landscape and Changes in Commercial Pipeline

The global brain tumor treatment market is currently led by Servier's IDH1/2 inhibitor voranigo, which received FDA approval in August 2024. However, telaglenastat has a unique mechanism of action with a distinct metabolic blockade pathway, giving it exclusive value as a next-generation combination partner. After the original developer, Calithera Biosciences, went bankrupt, Synhale Therapeutics acquired global rights in May 2025, restoring development momentum. The public clinical data supported by the National Cancer Institute (NCI) will serve as strong evidence for the future commercialization and partnership development of this pipeline.